Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03374241 · ClinicalTrials.gov registry record · Phase 1
A First-in-human Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of HM15211(Efocipegtrutide)
A Phase 1 study, sponsored by Hanmi Pharmaceutical Company Limited.
- Completed
- Registry status
- Phase 1
- Development phase
- 41
- Enrollment target
NCT03374241 is a Phase 1 study that has completed, run by Hanmi Pharmaceutical Company Limited. The registered enrollment target is 41 participants.
The verdict
NCT03374241, a Phase 1 study, has completed, sponsored by Hanmi Pharmaceutical Company Limited.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 41 participants
- Enrollment target
Study Summary
Single ascending dose of HM15211 in healthy obese subjects.
Interventions
- BIOLOGICAL HM15211 or Placebo
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 41 participants |
| Start Date | 2018-04-04 |
| Est. Completion | 2018-09-14 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03374241
The ClinicalTrials.gov registry entry for NCT03374241 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 41 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Hanmi Pharmaceutical Company Limited, which has 25 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which HM15211 or Placebo is the first listed.
NCT03374241 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03374241 about?
NCT03374241 is a clinical study titled "A First-in-human Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of HM15211(Efocipegtrutide)". Single ascending dose of HM15211 in healthy obese subjects.
What is the current status of trial NCT03374241?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 41 participants. The study started on 2018-04-04. Estimated completion is 2018-09-14.
What interventions are being tested in trial NCT03374241?
The interventions under investigation include: HM15211 or Placebo (BIOLOGICAL).
Who is sponsoring clinical trial NCT03374241?
This trial is sponsored by Hanmi Pharmaceutical Company Limited, which has 25 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.